Atossa Therapeutics (ATOS) FCF Margin (2011 - 2015)
Atossa Therapeutics (ATOS) posted quarterly FCF Margin of 72132.31% for Q4 2015, up 1542398.0% year-over-year from N/an in Q4 2014, and up 17.62% quarter-over-quarter from 87556.28% in Q4 2014.
Atossa Therapeutics (ATOS) FCF Margin (2011 - 2015) Analysis & Trends
Atossa Therapeutics (ATOS) has reported FCF Margin for 5 consecutive years, with 72132.31% the latest figure, recorded in Q4 2015.
- In Q4 2015, FCF Margin rose 1542398.0% year-over-year to 72132.31%; the TTM figure through Sep 2016 stood at 242768.15% (up 21527347.0% YoY), while the FY2015 annual figure was 643876.73%, down 61797478.0% from the prior year.
- FCF Margin climbed to 72132.31% in Q4 2015 per ATOS's latest filing, from 87556.28% in the prior quarter.
- Across five years, FCF Margin topped out at 703.62% in Q4 2013 and bottomed at 91714.86% in Q3 2014.
- Historically, FCF Margin has averaged 32255.45% across 5 years, with a median of 16907.13% in 2014.
- Annual changes were most pronounced in 2012 — FCF Margin surged 7055020 bps — and 2014, when it sank 8825990 bps.
- Atossa Therapeutics' FCF Margin stood at 72619.07% in 2011, then jumped by 97 bps to 2068.86% in 2012, then soared by 134 bps to 703.62% in 2013, then tumbled by 12544 bps to 87556.28% in 2014, then increased by 18 bps to 72132.31% in 2015.
- Business Quant data shows ATOS's FCF Margin at 72132.31% in Q4 2015, 87556.28% in Q4 2014, and 91714.86% in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 70.82% |
| 10 | Atossa Therapeutics | 22.72 Mn | 22.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -72,132.31% |
| Dec 31, 2014 | -87,556.28% |
| Sep 30, 2014 | -91,714.86% |
| Jun 30, 2014 | -23,007.79% |
| Mar 31, 2014 | -10,806.48% |
| Dec 31, 2013 | 703.62% |
| Sep 30, 2013 | -4,260.43% |
| Jun 30, 2013 | -1,750.61% |
| Mar 31, 2013 | -9,994.88% |
| Dec 31, 2012 | -2,068.86% |
| Sep 30, 2012 | -143.01% |
| Jun 30, 2012 | -25,967.90% |
| Mar 31, 2012 | -50,257.45% |
| Dec 31, 2011 | -72,619.07% |